State Street Corp Trims Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

State Street Corp reduced its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 5.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,849,588 shares of the biotechnology company's stock after selling 497,211 shares during the quarter. State Street Corp owned about 4.27% of BioCryst Pharmaceuticals worth $67,257,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. CWM LLC raised its holdings in shares of BioCryst Pharmaceuticals by 200.0% in the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 3,772 shares in the last quarter. Signaturefd LLC raised its stake in BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 5,599 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 1,322 shares during the last quarter. nVerses Capital LLC purchased a new position in BioCryst Pharmaceuticals in the 2nd quarter worth approximately $63,000. Finally, DRW Securities LLC bought a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter worth $74,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on BCRX. Barclays lifted their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a report on Tuesday, November 5th. Needham & Company LLC reaffirmed a "buy" rating and set a $14.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $15.60.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock traded down $0.18 during mid-day trading on Wednesday, hitting $7.31. The company's stock had a trading volume of 2,340,214 shares, compared to its average volume of 2,845,766. The business has a 50 day moving average price of $7.62 and a 200-day moving average price of $7.42. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $8.88. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -11.98 and a beta of 1.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.07). The company had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. During the same period last year, the firm posted ($0.19) EPS. The company's revenue was up 35.1% on a year-over-year basis. On average, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.